Biotech

All Articles

TPG leadings up funds to $580M for investments throughout life sciences

.Property supervisor TPG, which has assisted biotechs such as Sionna Therapeutics as well as Santa C...

Merck ceases phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT course has endured another drawback. Months after shuttering a period 3 mela...

After a hard year, Exscientia folds right into Recursion

.After a year determined through pipeline hairstyles, the variation of its CEO as well as cutbacks, ...

Cullinan, after $25M bargain, return bispecific to Port

.Cullinan Rehab was thrilled sufficient with Port BioMed's bispecific immune system reactor that it ...

A nearer look at Fierce Biotech's Fierce 15

.Within this full week's episode of "The Best Pipe," we are actually diving into Ferocious Biotech's...

Lilly faces period 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's party commemorating the approval of Alzheime...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant management hirings, firings and ...

Lykos will definitely inquire FDA to rethink its selection complying with denial of MDMA therapy for post-traumatic stress disorder

.Adhering to an unsatisfactory presenting for Lykos Therapies' MDMA candidate for trauma at a latest...

AN 2 fifty percents head count, quits phase 3 trial after data dissatisfy

.AN2 Rehabs is re-thinking its own business in reaction to lackluster midphase information, vowing t...

Merck pays out $700M for bispecific, snooping autoimmune opening as well as opportunity to test Amgen in cancer

.Merck &amp Co. is paying out $700 million ahead of time to challenge Amgen in a blood stream cancer...